The
Report EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) -
Epidemiology Forecast to 2025 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Lung
cancer is a disease of uncontrolled cell growth in the lung tissues.
It is one of the most commonly occurring cancers in the world (IARC,
2016). Lung cancer is classified into three main types: non-small
cell lung cancer (NSCLC), small cell lung cancer, and lung carcinoid
tumor. NSCLC is the most common type of lung cancer, making up about
85% of all lung cancers. Small cell lung cancer accounts for 10-15%
of lung cancers, while carcinoid tumors are the rarest, occurring in
fewer than 5% of lung cancers.
In
the 8MM, the diagnosed incident cases of NSCLC will increase from
791,563 cases in 2015 to 1,069,516 cases in 2025, at an Annual Growth
Rate (AGR) of 3.51% per year. When examining the AGR by individual
market, GlobalData forecasts that all markets will see an increase in
the diagnosed incident cases of NSCLC during the forecast period. In
2015, there were 1,199,845 five-year diagnosed prevalent cases of
NSCLC in the 8MM, which is expected to increase to 1,626,132 cases by
2025, at an AGR of 3.55%.
The
relative survival of NSCLC varies by subtype, where adenocarcinoma
has the highest survival, followed by squamous cell carcinoma, and
large cell carcinoma. In the alternate forecast, due to the forecast
increase in adenocarcinoma during 2015-2025, GlobalData
epidemiologists expect an increase in relative survival and,
consequently, an increase in the number of five-year diagnosed
prevalent cases of NSCLC.
GlobalData
epidemiologists also provided two forecasts to address potential
changes in the epidemiology of NSCLC during the forecast period
2015-2025: one in which the historical distribution of histology
subtypes are held constant throughout the forecast period, and an
alternate forecast where the histology subtypes are forecast to
change over time. The two forecasts provide different outlooks on the
market depending on the baseline assumptions.
View Report At
http://www.marketresearchreports.biz/analysis/901140
Scope
-
The Non-Small Cell Lung Cancer (NSCLC) EpiCast Report provides an
overview of the risk factors and global trends of NSCLC in the 8MM
(US, France, Germany, Italy, Spain, UK, Japan, and Urban China). It
also includes a 10-year epidemiology forecast of the diagnosed
incident and five-year diagnosed prevalent cases of NSCLC in these
markets from 2015-2025. The incident cases are further segmented by
sex and age, cancer stage at diagnosis (IA, IB, IIA, IIB, IIIA, IIIB,
and IV), cancer histology subtype (adenocarcinoma, squamous cell
carcinoma, large cell carcinoma, and other), and the presentation of
the biomarker mutations by histology subtype (EGFR, KRAS, ALK,
METExon 14, PIK3CA, BRAF V600E, and ROS1). The report also provides
an alternate forecast scenario that takes into account potential
changes in the diagnosed incident cases distribution by histology
subtype.
-
The NSCLC epidemiology report is written and developed by Masters-
and PhD-level epidemiologists.
-
The EpiCast Report is in-depth, high quality, transparent and
market-driven, providing expert analysis of disease trends in the
8MM.
Reasons to buy
The
NSCLC EpiCast report will allow you to -
-
Develop business strategies by understanding the trends shaping and
driving the global NSCLC market.
-
Quantify patient populations in the global NSCLC market to improve
product design, pricing, and launch plans.
-
Organize sales and marketing efforts by identifying the age groups
and sex that present the best opportunities for NSCLC therapeutics in
each of the markets covered.
-
Compare patient population potentials due to potential changes in
histology subtypes.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/901140
Table
of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Epidemiology 9
2.1 Disease Background 9
2.2 Risk Factors and Comorbidities
10
2.3 Global Trends 11
2.3.1 Incidence 11
2.3.2 Histological Subtypes 12
2.3.3 Relative Survival 13
2.4 Forecast Methodology 14
2.4.1 Sources Used 15
2.4.2 Forecast Assumptions and
Methods - Base Forecast 25
2.4.3 Forecast Assumptions and
Methods - Alternate Forecast 36
2.4.4 Sources Not Used 37
2.5 Epidemiological Forecast for
NSCLC (2015-2025) - Base Forecast 38
2.5.1 Diagnosed Incident Cases of
NSCLC 38
2.5.2 Age-Specific Diagnosed
Incident Cases of NSCLC 40
2.5.3 Sex-Specific Diagnosed
Incident Cases of NSCLC 42
2.5.4 Age-Standardized Diagnosed
Incidence of NSCLC 44
2.5.5 Diagnosed Incident Cases of
NSCLC by Clinical Stage at Diagnosis 45
2.5.6 Diagnosed Incident Cases of
NSCLC by Histology Subtype 46
2.5.7 Mutations Among Diagnosed
Incident Cases of Adenocarcinoma 47
2.5.8 Mutations Among Diagnosed
Incident Cases of Squamous Cell Carcinoma 48
2.5.9 Mutations Among Diagnosed
Incident Cases of NSCLC 49
2.5.10 Five-Year Diagnosed
Prevalent Cases of NSCLC 50
2.6 Epidemiological Forecast for
NSCLC (2015-2025) - Alternate Forecast 52
2.6.1 Alternate Forecast -
Diagnosed Incident Cases of NSCLC by Histology 52
2.6.2 Alternate Forecast -
Five-Year Diagnosed Prevalent Cases of NSCLC 54
2.7 Discussion 55
2.7.1 Epidemiological Forecast
Insight 55
2.7.2 Limitations of the Analysis
56
2.7.3 Strengths of the Analysis 57
3 Appendix 58
3.1 Bibliography 58
3.2 About the Authors 63
3.2.1 Epidemiologists 63
3.2.2 Reviewers 64
3.2.3 Global Director of Therapy
Analysis and Epidemiology 64
3.3 About GlobalData 65
3.4 About EpiCast 65
3.5 Disclaimer 66
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment